Orris

Severe PPHN in paediatric patients

Reading File
Finding Sources
Finding Sources
Finding Sources
Searching PubMed

"persistent pulmonary hypertension of the newborn" AND treatment

Searching the Web

severe persistent pulmonary hypertension newborn management guidelines 2025

Reading File
Reading File
Reading File
Reading File
Searching Images

persistent pulmonary hypertension of the newborn right-to-left shunt echocardiogram diagram

Severe Persistent Pulmonary Hypertension of the Newborn (PPHN)

What it is

PPHN is failure of the normal postnatal fall in pulmonary vascular resistance (PVR), so PVR stays at or returns to systemic/suprasystemic levels after birth. This keeps the ductus arteriosus and foramen ovale open, producing right-to-left shunting that bypasses the lungs - sometimes called "persistent fetal circulation" (Barash, Cullen, and Stoelting's Clinical Anesthesia, 9e, p. 3578).

Etiology and risk factors

Most commonly seen in term or post-term infants, those delivered by cesarean section, and neonates with fetal distress/low Apgar scores. Precipitating causes include:
  • Severe birth asphyxia, meconium aspiration syndrome, sepsis/pneumonia
  • Congenital diaphragmatic hernia (CDH) and other causes of pulmonary hypoplasia (renal agenesis)
  • Hyperviscosity syndrome (polycythemia)
  • In utero ductal constriction from maternal NSAID use
  • Maternal diabetes, maternal asthma
  • Often idiopathic
(The Harriet Lane Handbook, 23rd ed., p. 651; Barash, p. 3578)

Diagnostic features

PPHN typically presents within 12-24 hours of birth with:
  • Severe hypoxemia (PaO2 <35-45 mmHg in 100% O2) that is disproportionate to the degree of radiographic lung disease
  • A structurally normal heart with right-to-left shunting at the foramen ovale and/or ductus arteriosus
  • A significant pre-/postductal oxygen saturation gradient (≥7-15 mmHg)
  • It is critical to rule out cyanotic congenital heart disease: if oxygenation does not improve with supplemental O2, do a detailed cardiac exam, hyperoxia test, and echocardiogram
(Harriet Lane Handbook, p. 651-652)
Severity is graded using the Oxygenation Index (OI): OI = (Mean airway pressure × FiO2 × 100) / PaO2
An OI ≥15-25 signals significant disease requiring escalation of vasodilator therapy; severe PPHN is generally defined by OI >25-40 or refractory hypoxemia, and is the threshold used for ECMO consideration.

Management of severe PPHN

1. General supportive care
  • Correct predisposing/reversible factors: hypoglycemia, hypothermia, polycythemia, acidosis
  • Minimize handling/noxious stimuli; sedation (occasionally paralysis) in intubated infants
  • Maintain systemic blood pressure and perfusion with volume expansion and/or inotropes to reverse right-to-left shunting
  • Optimize oxygen-carrying capacity (transfusion as indicated)
  • Avoid severe hyperventilation/hypocarbia (PCO2 <30 mmHg) - risks myocardial ischemia, reduced cerebral blood flow, barotrauma, and chronic lung disease; gentle ventilation with adequate lung recruitment is preferred, with high-frequency ventilation and exogenous surfactant as adjuncts
  • Goal: PaO2 60-100 mmHg, normocapnia, preductal SpO2 typically 92-97% (some protocols target 93-98% in severe disease with acidosis/hypothermia)
2. Pulmonary vasodilator therapy
  • Inhaled nitric oxide (iNO) - the only FDA-approved agent for PPHN. Typical starting dose 20 ppm (lower, ~10 ppm, may suffice in preterm infants); little added benefit above 40 ppm. Watch for methemoglobinemia and NO2 toxicity. Response should be assessed within 30-60 minutes of initiation, and iNO should be started only with preserved LV systolic function - if severe LV dysfunction is found on echo after starting, iNO should be discontinued (per 2025 multidisciplinary consensus recommendations).
  • Sildenafil (PDE5 inhibitor) - increasing use, particularly where iNO is unavailable or as a weaning adjunct
  • Prostacyclin analogs (e.g., epoprostenol) - inhaled or IV
  • Bosentan (endothelin receptor antagonist) and milrinone - used as adjuvant therapy in refractory cases, though evidence is more limited
  • Point-of-care echocardiography is increasingly used to guide therapy and assess RV/LV function
3. Extracorporeal membrane oxygenation (ECMO) Reserved for severe cardiovascular instability or refractory hypoxemia:
  • OI >40 sustained for >3 hours, or
  • Alveolar-arterial O2 gradient ≥610 for 8 hours
  • Candidates typically need to be >2000 g and >34 weeks gestation
  • Obtain head ultrasound (± EEG) before cannulation to screen for intracranial hemorrhage
  • Meconium aspiration is the most common indication for neonatal ECMO and carries the highest survival among indications
(Harriet Lane Handbook, p. 652; Barash, p. 3578-3579; Sabiston Textbook of Surgery)

Prognosis

Survival correlates directly with successful correction of the underlying cause and the degree to which therapy lowers PVR. Ischemic encephalopathy and other hypoxic complications are major adverse prognostic factors. Maintaining right ventricular function is considered paramount to survival.

Recent evidence (worth flagging alongside textbook guidance)

A 2025 multidisciplinary consensus (CHOP) reinforces iNO at 20 ppm as first-line with the LV-function caveat above. A 2024 network meta-analysis comparing PPHN treatments and a 2024 systematic review of ECMO outcomes in PPHN are available for deeper reading if needed:
  • Fei Q et al. "Comparison of Different Treatments of PPHN: A Systematic Review and Network Meta-Analysis," Crit Care Med 2024 (PMID: 38363176)
  • Alhumaid S et al. "International treatment outcomes of neonates on ECMO with PPHN: a systematic review," J Cardiothorac Surg 2024 (PMID: 39182148)
  • Gao N et al. "Bosentan in the treatment of PPHN: a systematic review and meta-analysis," Cardiol Young 2024 (PMID: 38329072)
These don't contradict the textbook approach but add current comparative-effectiveness data on adjuvant vasodilators (sildenafil, bosentan, milrinone) beyond iNO monotherapy - useful if you're managing a case refractory to first-line iNO/ECMO criteria.
Let me know if you want me to go deeper into any specific piece - e.g., ECMO cannulation criteria and technique, the CDH-specific PPHN pathway, or a comparison of the vasodilator agents with dosing.

If ignophils what is the next line of treatment for a severe PPN

Interpreting "ignophils" as "if iNO [inhaled nitric oxide] fails" - the natural follow-up to first-line PPHN therapy. Let me pull targeted detail on refractory/iNO-non-responsive severe PPHN management.
Finding Sources
Finding Sources
Searching PubMed

"persistent pulmonary hypertension of the newborn" AND "nitric oxide" AND refractory

Searching the Web

refractory PPHN iNO failure next line treatment sildenafil milrinone ECMO

Reading "ignophils" as "if iNO fails" — here's the next-line approach for severe PPHN not responding to inhaled nitric oxide (iNO).

If iNO fails: stepwise escalation

1. Re-confirm the diagnosis and optimize the basics first Before escalating drugs, confirm you're not missing structural cyanotic heart disease (echo), and re-check the fundamentals: adequate lung recruitment/ventilation strategy, correction of acidosis/hypothermia/hypoglycemia, adequate sedation, and volume/inotrope status for systemic BP. A poorly recruited lung or ongoing acidosis will blunt iNO response regardless of dose.
2. Add or switch to a second pulmonary vasodilator
  • Sildenafil (PDE5 inhibitor) - most commonly added next; can be given IV or enteral. Useful especially where iNO access is limited, but note the Pfizer pediatric trial data showed sildenafil added to iNO did not significantly reduce treatment failure (need for ECMO/death) versus placebo + iNO - so it helps some infants but isn't guaranteed rescue.
  • Milrinone (PDE3 inhibitor, NO-independent) - increasingly used as an alternative/adjunct, particularly effective when there's concurrent LV diastolic dysfunction limiting iNO response (common in asphyxia, sepsis). Also supports RV function via inotropy. Growing evidence (case series/narrative reviews) supports it as an interim option, especially in centers with limited iNO/ECMO access.
  • Prostacyclin analogs (IV or inhaled epoprostenol, or IV treprostinil) - added for further pulmonary vasodilation, often in "triple therapy" (iNO + sildenafil + milrinone/prostacyclin).
  • Bosentan (endothelin receptor antagonist) - adjunct in some refractory cases, though evidence is weaker and onset slower, less useful as an acute rescue drug.
  • Vasopressin - has been used in case series for iNO-refractory PPHN in preterm neonates, working partly by increasing systemic pressure (favoring left-to-right flow) and having some pulmonary vasodilatory effect.
3. Reassess for reversible contributors
  • Check for LV dysfunction — if present, more pulmonary vasodilation (which increases pulmonary venous return to a failing LV) can worsen things; milrinone or careful inotrope choice matters here.
  • Consider sepsis, pneumothorax, or CDH-specific management if not already addressed.
4. Escalate to ECMO if refractory This is the definitive rescue. Move to ECMO if:
  • OI >40 sustained for >3 hours, or A-a gradient ≥610 for 8 hours (thresholds vary slightly by center)
  • Severe hemodynamic instability despite maximal vasodilator/inotrope therapy
  • Criteria: generally >2000 g, gestational age >34 weeks
  • Key practical point: don't wait until the infant is in extremis - early referral/transfer to an ECMO-capable center is strongly recommended once it's clear the infant is not responding to first-line therapy, since ECMO is the only intervention definitively shown to be lifesaving in severe refractory PPHN, and outcomes are better with earlier cannulation before multi-organ compromise sets in.

Summary order of escalation

iNO (first-line) → add sildenafil and/or milrinone (± prostacyclin) → consider bosentan/vasopressin as adjuncts in select cases → ECMO if hypoxemia/instability remains refractory despite maximal medical therapy.
This aligns with textbook management (Harriet Lane Handbook, Barash Clinical Anesthesia) and is consistent with recent literature, including a case series on milrinone as a bridge therapy and reviews confirming ECMO as the only proven lifesaving rescue once pharmacologic measures fail. If you're managing a specific case (e.g., with CDH, sepsis, or concurrent LV dysfunction), the optimal second agent differs - let me know the clinical context if you want a more tailored recommendation.
This is a shared conversation. Sign in to Orris to start your own chat.